Distance Traveled and Disparities in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Ian SolskyAna PatelGrey LeonardGregory RussellKathleen PerryKonstantinos I VotanopoulosPerry ShenEdward A LevinePublished in: Annals of surgical oncology (2023)
More than 50% of the patients traveled farther than 100 miles for treatment. Although regionalization of CRS/HIPEC may be appropriate given the lack of survival difference based on distance traveled, those who traveled further had fewer health care disparities but higher PCI scores and more R2 resections, which raises concerns about access to care for the underserved, time to treatment, and surgical quality.
Keyphrases
- healthcare
- patients undergoing
- end stage renal disease
- chronic kidney disease
- affordable care act
- minimally invasive
- quality improvement
- squamous cell carcinoma
- heart failure
- radiation therapy
- acute myocardial infarction
- percutaneous coronary intervention
- combination therapy
- coronary artery bypass
- patient reported outcomes
- replacement therapy
- pain management
- chronic pain
- smoking cessation